George Church spinoff swallows a key manufacturing partner as it preps CRISPR-edited pig organs for animal testing

Amber Tong

Researching, cloning and breeding gene-edited pigs are core to eGenesis’ audacious mission to grow organs that can be xenotransplanted into humans. But perhaps unsurprisingly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

George Church spinoff swallows a key manufacturing partner as it preps CRISPR-edited pig organs for animal testing

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

George Church spin­off swal­lows a key man­u­fac­tur­ing part­ner as it preps CRISPR-edit­ed pig or­gans for an­i­mal test­ing

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

George Church spinoff swallows a key manufacturing partner as it preps CRISPR-edited pig organs for animal testing